Emergent BioSolutions (NYSE:EBS) Shares Gap Up to $10.65

Emergent BioSolutions Inc. (NYSE:EBS)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $10.65, but opened at $11.00. Emergent BioSolutions shares last traded at $10.92, with a volume of 1,009,060 shares traded.

Analysts Set New Price Targets

Separately, Benchmark reiterated a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a report on Tuesday, July 2nd.

Emergent BioSolutions Stock Up 7.6 %

The business’s fifty day moving average is $6.21 and its two-hundred day moving average is $3.64. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($3.65) by $4.24. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. The firm had revenue of $300.40 million for the quarter. During the same period in the prior year, the firm posted ($3.17) EPS. Analysts predict that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current year.

Insider Activity at Emergent BioSolutions

In other news, Director Kathryn C. Zoon sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $6.11, for a total value of $61,100.00. Following the sale, the director now directly owns 54,482 shares in the company, valued at $332,885.02. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have sold 12,919 shares of company stock worth $75,831. Insiders own 1.20% of the company’s stock.

Institutional Trading of Emergent BioSolutions

Large investors have recently made changes to their positions in the stock. CoreCap Advisors LLC bought a new position in Emergent BioSolutions in the fourth quarter worth approximately $33,000. Avidian Wealth Solutions LLC purchased a new position in shares of Emergent BioSolutions during the first quarter valued at $33,000. Tidal Investments LLC purchased a new position in shares of Emergent BioSolutions during the first quarter valued at $34,000. CWM LLC raised its holdings in shares of Emergent BioSolutions by 32,706.7% in the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 4,906 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Emergent BioSolutions by 52.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 6,823 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.